Shadman, Venur named deputy CMOs and endowed chairs at Fred Hutch

Amid deepening controversy, Vinay Prasad, FDA’s top clinician and scientist, and director of its Center for Biologics Evaluation and Research, will be leaving the agency.

March 13, 2026

Vol.52 No.10

By Claire Marie Porter

In Brief

Vivek Subbiah to lead Early Drug Development Program at Stanford Cancer Institute

Vivek Subbiah has been appointed as the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026.

March 13, 2026

Vol.52 No.10

Shadman, Venur named deputy CMOs and endowed chairs at Fred Hutch

YOU MAY BE INTERESTED IN

Robert A. Winn named director of Fox Chase Cancer Center

Robert H. Vonderheide elected as AACR president-elect

AACR elects five members to board of directors

Kathleen N. Moore appointed deputy director and director of Phase I Oncology Trials Program at Fred & Pamela Buffett Cancer Center

Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)

Vivek Subbiah to lead Early Drug Development Program at Stanford Cancer Institute

Renew today!

Subscriber content

Never miss an issue!

Login